Arthur D. Little Announces Promotion of Seven New Partners as the Consultancy Continues Its Global Expansion
10.3.2021 11:00:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of seven of its consultants to the rank of Partner, in recognition of the expertise and depth of experience that each one brings to the company. These appointments represent a major milestone for ADL, with the company now boasting over 100 Partners within its global team. Over the past five years, ADL has doubled in size by pursuing a dynamic growth path, and one of the key tenets of its ongoing success is the development and promotion of its internal talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005042/en/
Arthur D. Little has reached the 100+ partners milestones, with the promotion of seven partners. (Photo: Business Wire)
The latest appointments to Partner are as follows:
- Matteo Ainardi, Partner, Automotive and Manufacturing (AMG) and Strategy & Organization (S&O) Practices. Matteo joined ADL in 2016 and currently leads the company’s global Aerospace & Defense Center of Competence. His main focus is on supporting clients in the A&D ecosystem, focusing on strategy definition, organizational redesign and innovation management.
- Lokesh Dadhich, Partner, Telecommunication, Information, Media & Electronics (TIME) and Operations Management (OM) Practices. Lokesh joined ADL in 2007 and is based out of the company’s Dubai office. His main areas of expertise are in Digital Strategy, Customer Experience, and Operations Excellence topics. He advises clients in the TIME industry and beyond on strategy, operations, and transformation challenges.
- Naoya Furuta, Partner, Operations Management (OM) Practice. Naoya joined ADL’s Tokyo office as a Manager in 2016, and has experience across multiple industries, with a particular focus on manufacturing and construction. His main areas of expertise include company-wide strategic planning, corporate management, corporate reform, M&A advisory and PMI.
- Trung Ghi, Partner, Energy & Utilities (ENUT) Practice. With more than 20 years of experience in the oil and gas industry, Trung currently leads ADL’s ENUT Practice in South-East Asia, and has been responsible for opening a number of key accounts. He has been a driving force in positioning ADL as a go-to management consulting firm within SEA’s energy sector.
- Max Scherr, Partner, Strategy & Organization (S&O) Practice. With over 20 years of experience in strategy consulting as a senior executive, Max joined ADL in 2018 and leads the company’s S&O Practice in its Vienna office. His specializations include Digital Transformation, Information Security, Growth and Corporate Strategy.
- Ben Thuriaux-Alemán, Partner, Energy & Utilities (ENUT) and Technology & Innovation Management (TIM) Practices. With over 20 years of consulting experience, Ben has played a major role in developing ADL’s TIM Practice, and currently runs the company’s Global Innovation Excellence Benchmarking diagnostic. His particular focus is on aligning innovation with corporate strategy, and working on national innovation initiatives.
- Marten Zieris, Partner, Strategy & Organization (S&O) Practice. Marten joined ADL in 2010 and is based out of its Frankfurt office. He is responsible for the company’s competence center “Organization & Transformation” in Central Europe and supports international clients in large-scale transformations end to end, “from concept development to implementation”. Marten also has a specialist focus on consumer products businesses.
Ignacio García Alves, Chairman and CEO of Arthur D. Little, comments: “I would like to congratulate these new Partners – and welcome them as the first members of ADL’s ‘Generation 100’! Each promotion is richly deserved and a recognition of the vital contribution that each Partner makes to our company. At ADL, we strive to employ and develop consultants who are both entrepreneurs and team players, and aspire to deliver consultancy at the highest level – as such, having over 100 Partners within ADL truly is a momentous achievement.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005042/en/
Contact information
Sue Glanville/Cate Bonthuys
Catalyst Comms
+44 7715 817589
info@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom